🔎 Trials Near Me

Home › Leucemia mieloide acuta › Oklahoma

Studi clinici su Leucemia mieloide acuta nello stato di Oklahoma

14 studi su Leucemia mieloide acuta cercano partecipanti presso sedi nello stato di Oklahoma.

Città nello stato di Oklahoma

Testo ufficiale dello studio (inglese)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Oklahoma City, Oklahoma City
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 3
6 Months – 21 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04293562

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 1
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT05886049

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • OU Health Stephenson Cancer Center, Oklahoma City
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Oklahoma Health Science Center, Oklahoma City
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545

Pilot Imaging Study of Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 1
Età da 4 a 80 · Tutti i sessi · Aggiornato il 23 apr 2026 · NCT03633955

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • OU Health Stephenson Cancer Center, Oklahoma City
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mar 2026 · NCT05735184

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

  • University of Oklahoma Health Sciences Center, Oklahoma City
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 mag 2024 · NCT04905810

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.